Groundbreaking AI Tool Enhances Blood Cancer Diagnosis, Say Researchers

Researchers from Memorial Sloan Kettering Cancer Center (MSK), UCSF, and UC Berkeley have introduced an AI tool called DeepHeme, enhancing the diagnosis of blood and bone marrow cancers. Traditional methods require manual cell counting and classification, often taking over 30 minutes. In contrast, DeepHeme can accomplish this in seconds, demonstrating expert-level accuracy after training on nearly 50,000 digital cell images. The tool not only aims to streamline diagnosis but also supports personalized medicine by potentially identifying new biomarkers. MSK plans to implement DeepHeme clinically following further validation and may license it to other institutions. The initiative is part of MSK’s broader goal to transition to a fully digital hematopathology service, improving the accessibility and reliability of patient data. AI tools like DeepHeme are designed to assist rather than replace human expertise, aiming for a collaborative approach to enhance cancer care and research outcomes.

Source link